【藥品性質提示】 根據 2019 AGS Beers Criteria,本藥品為【潛在不適當用藥 (PIM)】,不建議用於老年人。 |
Estradiol valerate, synthetic 17β-estradiol, is chemically and biologically identical to endogenous human estradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Medroxyprogesterone acetate (MPA) is a derivative of the natural progesterone, 17-alpha-hydroxy-6-methylprogesterone. MPA binds to progestin-specific receptors and acts on the endometrium to convert the status of the endometrium from proliferative to secretory.
Medroxyprogesterone acetate has a half-life of about 16 to 30 hours after oral doses; Estradiol undergoes extensive biotransformation. Its metabolites are excreted in the urine as glucuronide and sulfate conjugates together with a small proportion of unchanged estradiol. Besides urinary excretion, estrogen metabolites undergo an enterohepatic circulation.
Known, past or suspected breast cancer; Known, past or suspected oestrogen dependent malignant tumour; Active thrombophlebitis, active or recent arterial thromboembolic disease, active or history of venous thromboembolism (VTE); Thrombophilic disorders; Acute liver disease, history of liver disease where LFTs have failed to return to normal. Severe renal impairment; Untreated endometrial hyperplasia; undiagnosed vaginal bleeding; Porphyria; Pregnancy, lactation.
X
Avoided. Medroxyprogesterone is reported to be distributed into breast milk.
Breast tenderness/pain and enlargement, sodium/fluid retention, mood and libido changes, asthenia, headache, migraine, dizziness, insomnia, GI upset, wt change, leg cramps, vaginitis, menstrual disorders, change in vaginal secretion, Breakthrough bleeding.
One tablet each day orally without a tablet-free interval. Tablet should be taken approximately at the same time of the day.